Title 21Food and DrugsRelease 119-73

§379dd–2 Activities of the Food and Drug Administration

Title 21 › Chapter CHAPTER 9— - FEDERAL FOOD, DRUG, AND COSMETIC ACT › Subchapter SUBCHAPTER VII— - GENERAL AUTHORITY › Part Part I— - Reagan-Udall Foundation for the Food and Drug Administration › § 379dd–2

Last updated Apr 6, 2026|Official source

Summary

The Commissioner must get and review the report the Foundation’s Executive Director sends under the law. Starting in fiscal year 2009, the Commissioner must also send Congress a yearly summary that explains how information from that Foundation report and from other recipients of grants, contracts, memoranda of understanding, or cooperative agreements has been used in FDA rulemaking and product reviews. The rules in this part and in a related provision do not change or affect any FDA grant, contract, memorandum of understanding, or cooperative agreement with any other entity, whether made before, on, or after September 27, 2007.

Full Legal Text

Title 21, §379dd–2

Food and Drugs — Source: USLM XML via OLRC

(a)The Commissioner shall receive and assess the report submitted to the Commissioner by the Executive Director of the Foundation under section 379dd(l)(2) of this title.
(b)Beginning with fiscal year 2009, the Commissioner shall submit to Congress an annual report summarizing the incorporation of the information provided by the Foundation in the report described under section 379dd(l)(2) of this title and by other recipients of grants, contracts, memoranda of understanding, or cooperative agreements into regulatory and product review activities of the Food and Drug Administration.
(c)The provisions of this part and section 360bbb–5 of this title shall have no effect on any grant, contract, memorandum of understanding, or cooperative agreement between the Food and Drug Administration and any other entity entered into before, on, or after September 27, 2007.

Reference

Citations & Metadata

Citation

21 U.S.C. § 379dd–2

Title 21Food and Drugs

Last Updated

Apr 6, 2026

Release point: 119-73